HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced that the U.S. Food and Drug Administration (FDA) has accepted its HeartBeam System into the Total Product Life Cycle Advisory Program (TAP) Pilot. The acceptance follows the receipt of Breakthrough Device Designation earlier this month and applies to the company's 3D electrocardiogram (ECG) technology being developed to assess potential heart attacks outside traditional medical settings.
The TAP program provides dedicated FDA advisors, expedited regulatory feedback, and access to healthcare providers, patient advocacy groups, and insurers to help accelerate development and patient access. For HeartBeam, this means a more collaborative and efficient path to market for its heart attack assessment technology, which is not currently cleared for that indication. The company estimates the heart attack assessment market opportunity at approximately $15 billion within a broader cardiac platform opportunity exceeding $40 billion.
HeartBeam expects to seek FDA alignment on its multicenter pivotal study design in the coming months, with patient enrollment anticipated to begin in the first quarter of 2027. The study is intended to support a future regulatory submission expanding the HeartBeam System's indications to include heart attack assessment. The company is also evaluating eligibility for the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, designed to accelerate Medicare access to eligible Breakthrough devices.
The HeartBeam System is not currently cleared for heart attack detection, and TAP participation does not guarantee future FDA authorization or insurance coverage. However, the company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement, positioning it as a potential leader in portable cardiac monitoring.
For readers, this announcement signals a significant step toward more accessible cardiac care. If successful, HeartBeam's technology could enable heart attack assessment outside of hospitals, potentially reducing time to treatment and improving outcomes. Investors may see this as a validation of HeartBeam's technology and a catalyst for future growth, given the large addressable market. The company's progress will be closely watched as it advances its pivotal study and seeks to expand its indications.
To view the full press release, visit https://nnw.fm/NdfEK. For more information about HeartBeam, visit HeartBeam (NASDAQ: BEAT). The latest news and updates relating to BEAT are available in the company's newsroom at https://nnw.fm/BEAT. Details on the intended use of its technology can be found at https://www.heartbeam.com/indications.
NetworkNewsWire, a specialized communications platform, distributed this announcement. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which offers InvestorWire for wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.
